{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T19:11:22Z","timestamp":1771009882900,"version":"3.50.1"},"reference-count":101,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T00:00:00Z","timestamp":1225497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1002\/jps.21367","type":"journal-article","created":{"date-parts":[[2008,3,19]],"date-time":"2008-03-19T21:46:37Z","timestamp":1205963197000},"page":"4915-4933","source":"Crossref","is-referenced-by-count":61,"title":["Amorphous cyclosporin nanodispersions for enhanced pulmonary deposition and dissolution"],"prefix":"10.1016","volume":"97","author":[{"given":"Jasmine M.","family":"Tam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason T.","family":"McConville","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"Robert O.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith P.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1002\/jps.21367_bb0010","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/0168-3659(94)90081-7","article-title":"Pulmonary delivery of therapeutic peptides and proteins","volume":"29","author":"Adjei","year":"1994","journal-title":"J Control Release"},{"key":"10.1002\/jps.21367_bb0015","series-title":"Inhalation delivery of therapeutic peptides and proteins","first-page":"913","author":"Adjei","year":"1997"},{"key":"10.1002\/jps.21367_bb0020","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v19.i45.40","article-title":"Pulmonary drug delivery systems: Recent developments and prospects","volume":"19","author":"Courrier","year":"2002","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"10.1002\/jps.21367_bb0025","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v20.i5.10","article-title":"Aerosol treatment of cystic fibrosis","volume":"20","author":"Garcia-Contreras","year":"2003","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"10.1002\/jps.21367_bb0030","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0169-409X(03)00076-0","article-title":"Aerosol delivery and asthma therapy","volume":"55","author":"Hickey","year":"2003","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1002\/jps.21367_bb0035","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/bdd.2510150406","article-title":"Pharmacokinetics of SDZ 64-412, a novel antiasthmatic agent, following intravenous, oral, and inhalation dosing in the rat","volume":"15","author":"Charnick","year":"1994","journal-title":"Biopharm Drug Dispos"},{"key":"10.1002\/jps.21367_bb0040","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/nrd1494","article-title":"Nanosuspensions in drug delivery","volume":"3","author":"Rabinow","year":"2004","journal-title":"Nature Rev Drug Discov"},{"key":"10.1002\/jps.21367_bb0045","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00118-6","article-title":"Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future","volume":"47","author":"Muller","year":"2001","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1002\/jps.21367_bb0050","doi-asserted-by":"crossref","first-page":"12001","DOI":"10.1073\/pnas.182233999","article-title":"Trojan particles: Large porous carriers of nanoparticles for drug delivery","volume":"99","author":"Tsapis","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1002\/jps.21367_bb0055","series-title":"Clearance of particles deposited in the lungs","author":"Kreyling","year":"2000"},{"key":"10.1002\/jps.21367_bb0060","series-title":"Effects and fate of inhaled ultrafine particles","first-page":"37","author":"Oberdoerster","year":"2005"},{"key":"10.1002\/jps.21367_bb0065","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3109\/03009739009178581","article-title":"Intrapulmonary deposition of aerosolized Evans blue dye and liposomes in an experimental porcine model of early ARDS","volume":"95","author":"Forsgren","year":"1990","journal-title":"Ups J Med Sci"},{"key":"10.1002\/jps.21367_bb0070","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0168-3659(97)00149-1","article-title":"Relating the phagocytosis of microparticles by alveolar macrophages to surface chemistry: The effect of 1,2-dipalmitoylphosphatidylcholine","volume":"51","author":"Evora","year":"1998","journal-title":"J Control Release"},{"key":"10.1002\/jps.21367_bb0075","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jconrel.2005.06.009","article-title":"Microparticle-based lung delivery of INH decreases INH metabolism and targets alveolar macrophages","volume":"107","author":"Zhou","year":"2005","journal-title":"J Control Release"},{"key":"10.1002\/jps.21367_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/01902148509061524","article-title":"Association of 59iron oxide with alveolar macrophages during alveolar clearance","volume":"9","author":"Lehnert","year":"1985","journal-title":"Exp Lung Res"},{"key":"10.1002\/jps.21367_bb0085","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1126\/science.276.5320.1868","article-title":"Large porous Particles for pulmonary delivery","volume":"276","author":"Edwards","year":"1997","journal-title":"Science"},{"key":"10.1002\/jps.21367_bb0090","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jconrel.2004.02.018","article-title":"Poly(ether-anhydride) dry powder aerosols for sustained drug delivery in the lungs","volume":"96","author":"Fiegel","year":"2004","journal-title":"J Control Release"},{"key":"10.1002\/jps.21367_bb0095","first-page":"489","article-title":"Gene delivery to the lung","volume":"134","author":"Hanes","year":"2004","journal-title":"Drugs Pharm Sci"},{"key":"10.1002\/jps.21367_bb0100","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/0021-8502(84)90007-7","article-title":"Mathematical models of particle deposition in the human respiratory tract","volume":"15","author":"Heyder","year":"1984","journal-title":"J Aerosol Sci"},{"key":"10.1002\/jps.21367_bb0105","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/0021-8502(86)90035-2","article-title":"Deposition of particles in the human respiratory tract in the size range 0.005-15 [mu]m","volume":"17","author":"Heyder","year":"1986","journal-title":"J Aerosol Sci"},{"key":"10.1002\/jps.21367_bb0110","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1021\/ie0513191","article-title":"Novel formulation of large hollow nanoparticles aggregates as potential carriers in inhaled delivery of nanoparticulate drugs","volume":"45","author":"Hadinoto","year":"2006","journal-title":"Ind Eng Chem Res"},{"key":"10.1002\/jps.21367_bb0115","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1023\/A:1014276917363","article-title":"Production and characterization of a budesonide nanosuspension for pulmonary administration","volume":"19","author":"Jacobs","year":"2002","journal-title":"Pharm Res"},{"key":"10.1002\/jps.21367_bb0120","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s11095-006-9904-6","article-title":"Targeted high lung concentrations of itraconazole using nebulized dispersions in a murine model","volume":"23","author":"McConville","year":"2006","journal-title":"Pharm Res"},{"key":"10.1002\/jps.21367_bb0125","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ejpb.2006.01.006","article-title":"Single dose and multiple dose studies of itraconazole nanoparticles","volume":"63","author":"Vaughn","year":"2006","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1002\/jps.21367_bb0130","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0378-5173(88)90147-0","article-title":"Development of a systematic theory of suspension inhalation aerosols. II. Aggregates of monodisperse particles nebulized in polydisperse droplets","volume":"41","author":"Chan","year":"1988","journal-title":"Int J Pharm"},{"key":"10.1002\/jps.21367_bb0135","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0939-6411(99)00049-1","article-title":"An in-vitro assessment of a NanoCrystal beclomethasone dipropionate colloidal dispersion via ultrasonic nebulization","volume":"48","author":"Ostrander","year":"1999","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1002\/jps.21367_bb0140","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1093\/jac\/dki027","article-title":"Antitubercular inhaled therapy: Opportunities, progress and challenges","volume":"55","author":"Pandey","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1002\/jps.21367_bb0145","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0168-3659(99)00048-6","article-title":"Pulmonary delivery of insulin with nebulized dl-lactide\/glycolide copolymer (PLGA) nanospheres to prolong hypoglycemic effect","volume":"62","author":"Kawashima","year":"1999","journal-title":"J Control Release"},{"key":"10.1002\/jps.21367_bb0150","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0378-5173(01)00614-7","article-title":"Prolonged hypoglycemic effect of insulin-loaded polybutylcyanoacrylate nanoparticles after pulmonary administration to normal rats","volume":"218","author":"Zhang","year":"2001","journal-title":"Int J Pharm"},{"key":"10.1002\/jps.21367_bb0155","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0928-4931(02)00017-6","article-title":"Polymeric nanospheres fabricated with natural emulsifiers for clinical administration of an anticancer drug paclitaxel (Taxol)","volume":"C20","author":"Feng","year":"2002","journal-title":"Mater Sci Eng C Biomimetic Supramol Syst"},{"key":"10.1002\/jps.21367_bb0160","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0168-3659(03)00359-6","article-title":"Agglomerated vesicle technology: A new class of particles for controlled and modulated pulmonary drug delivery","volume":"93","author":"Bhavane","year":"2003","journal-title":"J Control Release Off J Control Release Soc"},{"key":"10.1002\/jps.21367_bb0165","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0939-6411(00)00087-4","article-title":"Solid lipid nanoparticles (SLN) for controlled drug delivery\u2014A review of the state of the art","volume":"50","author":"Muller","year":"2000","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1002\/jps.21367_bb0170","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v15.i6.30","article-title":"Novel methods of insulin delivery: An update","volume":"15","author":"Chetty","year":"1998","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"10.1002\/jps.21367_bb0175","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jconrel.2004.02.010","article-title":"Cyclodextrins as a potential carrier in drug nebulization","volume":"96","author":"Evrard","year":"2004","journal-title":"J Control Release"},{"key":"10.1002\/jps.21367_bb0180","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/0378-5173(91)90331-H","article-title":"Studies of cyclodextrin inclusion complexes. IV. The pulmonary absorption of salbutamol from a complex with 2-hydroxypropyl-b-cyclodextrin in rabbits","volume":"77","author":"Cabral Marques","year":"1991","journal-title":"Int J Pharm"},{"key":"10.1002\/jps.21367_bb0185","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/0091270003261490","article-title":"The pharmacokinetics of nebulized nanocrystal budesonide suspension in healthy volunteers","volume":"44","author":"Kraft","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"10.1002\/jps.21367_bb0190","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0169-409X(03)00078-4","article-title":"Novel alternative methods for the delivery of drugs for the treatment of asthma","volume":"55","author":"Chan","year":"2003","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1002\/jps.21367_bb0195","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1081\/DDC-54311","article-title":"Three generations of cyclosporine a formulations: An in vitro comparison","volume":"31","author":"Thomas","year":"2005","journal-title":"Drug Dev Ind Pharm"},{"key":"10.1002\/jps.21367_bb0200","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1183\/09031936.03.00018202","article-title":"A cyclosporin A\/maltosyl-a-cyclodextrin complex for inhalation therapy of asthma","volume":"22","author":"Fukaya","year":"2003","journal-title":"Eur Respir J"},{"key":"10.1002\/jps.21367_bb0205","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1021\/bm060130l","article-title":"Polyelectrolyte nanoparticles with high drug loading enhance the oral uptake of hydrophobic compounds","volume":"7","author":"Cheng","year":"2006","journal-title":"Biomacromolecules"},{"key":"10.1002\/jps.21367_bb0210","series-title":"Cyclosporin A: Solubilization, solid dispersion, and solid state transformation. Industrial and physical pharmacy","author":"Zhou","year":"2000"},{"key":"10.1002\/jps.21367_bb0215","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.2042-7158.1991.tb06688.x","article-title":"Unusual solubility behaviour of cyclosporin A in aqueous media","volume":"43","author":"Ismailos","year":"1991","journal-title":"J Pharm Pharmacol"},{"key":"10.1002\/jps.21367_bb0220","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1164\/ajrccm\/138.5.1242","article-title":"Evaluation of the in vitro and in vivo effects of cyclosporine on the lung T-lymphocyte alveolitis of active pulmonary sarcoidosis","volume":"138","author":"Martinet","year":"1988","journal-title":"Am Rev Respir Dis"},{"key":"10.1002\/jps.21367_bb0225","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1016\/S0003-4975(99)01183-2","article-title":"Pharmacokinetics of liposomal aerosolized cyclosporine A for pulmonary immunosuppression","volume":"68","author":"Letsou","year":"1999","journal-title":"Ann Thorac Surg"},{"key":"10.1002\/jps.21367_bb0230","first-page":"333","article-title":"Local immunosuppression: The lung","volume":"29","author":"Iacono","year":"2001","journal-title":"Immunol Med Ser"},{"key":"10.1002\/jps.21367_bb0235","doi-asserted-by":"crossref","first-page":"472","DOI":"10.2165\/00003088-199324060-00004","article-title":"Cyclosporin clinical pharmacokinetics","volume":"24","author":"Fahr","year":"1993","journal-title":"Clin Pharmacokinet"},{"key":"10.1002\/jps.21367_bb0240","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/00007890-199907270-00005","article-title":"Nebulized cyclosporine in the rat: Assessment of regional lung and extrapulmonary deposition","volume":"68","author":"Blot","year":"1999","journal-title":"Transplantation"},{"key":"10.1002\/jps.21367_bb0245","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0022-5223(98)70439-8","article-title":"Aerosol cyclosporine prevents acute allograft rejection in experimental lung transplantation","volume":"115","author":"Mitruka","year":"1998","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1002\/jps.21367_bb0250","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S1053-2498(00)00176-5","article-title":"In the lung aerosol cyclosporine provides a regional concentration advantage over intramuscular cyclosporine","volume":"19","author":"Mitruka","year":"2000","journal-title":"J Heart Lung Transplant Off Publ Int Soc Heart Transplant"},{"key":"10.1002\/jps.21367_bb0255","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/00007890-199201000-00003","article-title":"Improved immunosuppression with aerosolized cyclosporine in experimental pulmonary transplantation","volume":"53","author":"Keenan","year":"1992","journal-title":"Transplantation"},{"key":"10.1002\/jps.21367_bb0260","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0022-5223(97)70331-3","article-title":"Treatment of refractory acute allograft rejection with aerosolized cyclosporine in lung transplant recipients","volume":"113","author":"Keenan","year":"1997","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1002\/jps.21367_bb0265","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1183\/09031936.04.00058504","article-title":"Aerosol cyclosporin therapy in lung transplant recipients with bronchiolitis obliterans","volume":"23","author":"Iacono","year":"2004","journal-title":"Eur Respir J"},{"key":"10.1002\/jps.21367_bb0270","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJMoa043204","article-title":"A randomized trial of inhaled cyclosporine in lung-transplant recipients","volume":"354","author":"Iacono Aldo","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1002\/jps.21367_bb0275","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1023\/A:1022275222207","article-title":"Lung deposition and pharmacokinetics of cyclosporine after aerosolization in lung transplant patients","volume":"20","author":"Burckart","year":"2003","journal-title":"Pharm Res"},{"key":"10.1002\/jps.21367_bb0280","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3109\/10611869909085494","article-title":"Nebulizer-compatible liquid formulations for aerosol pulmonary delivery of hydrophobic drugs: Glucocorticoids and cyclosporine","volume":"7","author":"Klyashchitsky","year":"1999","journal-title":"J Drug Target"},{"key":"10.1002\/jps.21367_bb0285","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1097\/00007890-199310000-00037","article-title":"Characterization and administration of cyclosporine liposomes as a small-particle aerosol","volume":"56","author":"Gilbert","year":"1993","journal-title":"Transplantation"},{"key":"10.1002\/jps.21367_bb0290","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0378-5173(97)00322-0","article-title":"Experimental pulmonary delivery of cyclosporin A by liposome aerosol","volume":"160","author":"Waldrep","year":"1998","journal-title":"Int J Pharm"},{"key":"10.1002\/jps.21367_bb0295","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0378-5173(90)90287-E","article-title":"The stability of liposomes to nebulisation","volume":"58","author":"Taylor","year":"1990","journal-title":"Int J Pharm"},{"key":"10.1002\/jps.21367_bb0300","doi-asserted-by":"crossref","first-page":"8951","DOI":"10.1021\/la061122t","article-title":"Drug nanoparticles by antisolvent precipitation: Mixing energy versus surfactant stabilization","volume":"22","author":"Matteucci","year":"2006","journal-title":"Langmuir"},{"key":"10.1002\/jps.21367_bb0305","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0378-5173(02)00147-3","article-title":"Preparation of cyclosporine A nanoparticles by evaporative precipitation into aqueous solution","volume":"242","author":"Chen","year":"2002","journal-title":"Int J Pharm"},{"key":"10.1002\/jps.21367_bb0310","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1021\/mp0700211","article-title":"Design of potent amorphous drug nanoparticles for rapid generation of highly supersaturated media","volume":"4","author":"Matteucci","year":"2007","journal-title":"Mol Pharm"},{"key":"10.1002\/jps.21367_bb0315","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1023\/B:PHAM.0000048196.61887.e5","article-title":"Development and characterization of a scalable controlled precipitation process to enhance the dissolution of poorly water-soluble drugs","volume":"21","author":"Rogers","year":"2004","journal-title":"Pharm Res"},{"key":"10.1002\/jps.21367_bb0320","doi-asserted-by":"crossref","first-page":"20155","DOI":"10.1021\/jp0532521","article-title":"Electrostatically stabilized metal oxide particle dispersions in carbon dioxide","volume":"109","author":"Smith","year":"2005","journal-title":"J Phys Chem B"},{"key":"10.1002\/jps.21367_bb0325","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/clinchem\/27.8.1368","article-title":"Liquid-chromatographic determination of cyclosporin A in blood and plasma","volume":"27","author":"Sawchuk","year":"1981","journal-title":"Clin Chem (Washington, DC)"},{"key":"10.1002\/jps.21367_bb0330","series-title":"Species differences in aerosol deposition","first-page":"23","author":"McMahon","year":"1977"},{"key":"10.1002\/jps.21367_bb0335","first-page":"122","article-title":"Anatomical deposition and early distribution of an inhaled radioaerosol in conscious and anaesthetized rats","volume":"87","author":"Gazeley","year":"1986","journal-title":"Br J Pharmacol"},{"key":"10.1002\/jps.21367_bb0340","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/02786829308959603","article-title":"Lower respiratory tract structure of laboratory animals and humans: Dosimetry implications","volume":"18","author":"Miller","year":"1993","journal-title":"Aerosol Sci Technol"},{"key":"10.1002\/jps.21367_bb0345","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0169-409X(95)00113-L","article-title":"Mechanisms of macromolecule absorption by the lungs","volume":"19","author":"Patton","year":"1996","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1002\/jps.21367_bb0350","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.supflu.2005.10.004","article-title":"Micronization of cyclosporine using dense gas techniques","volume":"37","author":"Tandya","year":"2006","journal-title":"J Supercritical Fluids"},{"key":"10.1002\/jps.21367_bb0355","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1211\/0022357056208","article-title":"Thermotropic liquid crystalline drugs","volume":"57","author":"Bunjes","year":"2005","journal-title":"J Pharm Pharmacol"},{"key":"10.1002\/jps.21367_bb0360","doi-asserted-by":"crossref","DOI":"10.1103\/PhysRevLett.98.036102","article-title":"Ostwald ripening of b-carotene nanoparticles","volume":"98","author":"Liu","year":"2007","journal-title":"Phys Rev Lett"},{"key":"10.1002\/jps.21367_bb0365","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1517\/13543784.12.4.647","article-title":"A new class of cyclosporin analogues for the treatment of asthma","volume":"12","author":"Eckstein Jens","year":"2003","journal-title":"Expert Opinion Invest Drugs"},{"key":"10.1002\/jps.21367_bb0370","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1021\/bp000032q","article-title":"Rapid expansion from supercritical to aqueous solution to produce submicron suspensions of water-insoluble drugs","volume":"16","author":"Young","year":"2000","journal-title":"Biotechnol Prog"},{"key":"10.1002\/jps.21367_bb0375","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ijpharm.2007.02.014","article-title":"Murine airway histology and intracellular uptake of inhaled amorphous itraconazole","volume":"338","author":"Vaughn","year":"2007","journal-title":"Int J Pharm"},{"key":"10.1002\/jps.21367_bb0380","series-title":"Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b","first-page":"18","author":"Balwani","year":"2003"},{"key":"10.1002\/jps.21367_bb0385","series-title":"Flash nanoprecipitation of organic actives via confined micromixing and block copolymer stabilization","first-page":"18","author":"Johnson","year":"2003"},{"key":"10.1002\/jps.21367_bb0390","series-title":"American Association of Pharmaceutical Sciences","first-page":"18","author":"Matteucci","year":"2004"},{"key":"10.1002\/jps.21367_bb0395","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0378-5173(97)04912-0","article-title":"High dose cyclosporin A and budesonide-liposome aerosols","volume":"152","author":"Waldrep","year":"1997","journal-title":"Int J Pharm"},{"key":"10.1002\/jps.21367_bb0400","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0378-5173(00)00477-4","article-title":"An investigation of some of the factors influencing the jet nebulization of liposomes","volume":"204","author":"Bridges","year":"2000","journal-title":"Int J Pharm"},{"key":"10.1002\/jps.21367_bb0405","series-title":"Intermolecular and surface forces","author":"Israelachvili","year":"1992"},{"key":"10.1002\/jps.21367_bb0410","series-title":"Medical Intelligence Unit","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/978-3-662-22105-1_13","article-title":"Local Immunosuppression of Organ Transplants","author":"Burckart","year":"1996"},{"key":"10.1002\/jps.21367_bb0415","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/0034-5687(71)90009-0","article-title":"Morphometric estimation of pulmonary diffusion capacity. 3. The effect of increased oxygen consumption in Japanese Waltzing mice","volume":"11","author":"Geelhaar","year":"1971","journal-title":"Respir Physiol"},{"key":"10.1002\/jps.21367_bb0420","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1152\/jappl.1987.62.5.1865","article-title":"A species comparison of alveolar size and surface forces","volume":"62","author":"Lum","year":"1987","journal-title":"J Appl Physiol"},{"key":"10.1002\/jps.21367_bb0425","series-title":"Unit operations of chemical engineering","author":"McCabe","year":"2001"},{"key":"10.1002\/jps.21367_bb0430","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ejpb.2005.02.010","article-title":"Human respiratory epithelial cell culture for drug delivery applications","volume":"60","author":"Forbes","year":"2005","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1002\/jps.21367_bb0435","series-title":"Pharmaceutical inhalation aerosol technology","first-page":"340","author":"Niven","year":"1992"},{"key":"10.1002\/jps.21367_bb0440","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0378-5173(03)00091-7","article-title":"A novel method for assessing dissolution of aerosol inhaler products","volume":"255","author":"Davies","year":"2003","journal-title":"Int J Pharm"},{"key":"10.1002\/jps.21367_bb0445","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0168-3659(01)00475-8","article-title":"Enhanced pulmonary absorption following aerosol administration of mucoadhesive powder microspheres","volume":"77","author":"Sakagami","year":"2001","journal-title":"J Control Release"},{"key":"10.1002\/jps.21367_bb0450","first-page":"355","article-title":"Absorption of aerosolized drugs from the rat lung","volume":"11","author":"Brown","year":"1983","journal-title":"Drug Metab Dispos"},{"key":"10.1002\/jps.21367_bb0455","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1152\/ajplegacy.1972.223.5.1227","article-title":"Absorption of drugs from the rat lung","volume":"223","author":"Enna","year":"1972","journal-title":"Am J Physiol"},{"key":"10.1002\/jps.21367_bb0460","first-page":"79","article-title":"Species comparison of drug absorption from the lung after aerosol inhalation or intratracheal injection","volume":"14","author":"Schanker","year":"1986","journal-title":"Drug Metab Dispos"},{"key":"10.1002\/jps.21367_bb0465","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1126\/science.6238408","article-title":"Cyclophilin: A specific cytosolic binding protein for cyclosporin A","volume":"226","author":"Handschumacher","year":"1984","journal-title":"Science (Washington, DC)"},{"key":"10.1002\/jps.21367_bb0470","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0169-409X(95)00101-C","article-title":"Do interactions with phospholipids contribute to the prolonged retention of polypeptides within the lung?","volume":"19","author":"McAllister","year":"1996","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1002\/jps.21367_bb0475","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/00007890-198901000-00005","article-title":"Prolongation of heterotopic heart allograft survival by local delivery of continuous low-dose cyclosporine therapy","volume":"47","author":"Stepkowski","year":"1989","journal-title":"Transplantation"},{"key":"10.1002\/jps.21367_bb0480","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1046\/j.0306-5251.2001.01493.x","article-title":"Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler","volume":"52","author":"Thorsson","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1002\/jps.21367_bb0485","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1183\/09031936.97.10071496","article-title":"Distribution of inhaled fluticasone propionate between human lung tissue and serum in vivo","volume":"10","author":"Esmailpour","year":"1997","journal-title":"Eur Respir J"},{"key":"10.1002\/jps.21367_bb0490","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1513\/pats.200409-049TA","article-title":"The Lungs as a Portal of Entry for Systemic Drug Delivery","volume":"1","author":"Patton","year":"2004","journal-title":"Proc Am Thorac Soc"},{"key":"10.1002\/jps.21367_bb0495","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1080\/03639040500388573","article-title":"Enhancing the bioavailability of cyclosporine A using solid dispersion containing polyoxyethylene (40) stearate","volume":"32","author":"Liu","year":"2006","journal-title":"Drug Dev Ind Pharm"},{"key":"10.1002\/jps.21367_bb0500","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1006\/clin.1996.0140","article-title":"The mechanism of action of cyclosporin A and FK506","volume":"80","author":"Ho","year":"1996","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1002\/jps.21367_bb0505","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1056\/NEJM198912213212507","article-title":"Cyclosporine","volume":"321","author":"Kahan","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1002\/jps.21367_bb0510","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1097\/00004032-196412000-00019","article-title":"Alveolar reactivity following inhalation of particles","volume":"10","author":"Casarett","year":"1964","journal-title":"Health Phys"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354916327757?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354916327757?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,3]],"date-time":"2020-05-03T07:39:40Z","timestamp":1588491580000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354916327757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":101,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["S0022354916327757"],"URL":"https:\/\/doi.org\/10.1002\/jps.21367","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2008,11]]}}}